Variable name;level;Overall;Yes;No;p;test
;n;262;175;87;;
Age;[0 -30);63 (24.0);45 (25.7);18 (20.7);0.401;
;[30 -35);119 (45.4);82 (46.9);37 (42.5);;
;[35 -40);76 (29.0);45 (25.7);31 (35.6);;
;40+;4 (1.5);3 (1.7);1 (1.1);;
Age (mean);;32.7 (3.7);32.5 (3.8);33.3 (3.6);0.103;
Number of children;0;177 (67.6);119 (68.0);58 (66.7);0.856;
;1;53 (20.2);36 (20.6);17 (19.5);;
;More than 1;32 (12.2);20 (11.4);12 (13.8);;
BMI;<18.5;16 (6.3);4 (2.4);12 (14.1);0.003;
;25-29.9;46 (18.0);34 (20.0);12 (14.1);;
;>=30;12 (4.7);9 (5.3);3 (3.5);;
;18.5-24.9;181 (71.0);123 (72.4);58 (68.2);;
BMI (mean);;22.0 [20.3, 24.5];22.6 [20.4, 25.1];21.5 [19.9, 24.1];0.033;nonnorm
Treatment center;Curie Paris;168 (64.1);114 (65.1);54 (62.1);NaN;
;Curie St Cloud;94 (35.9);61 (34.9);33 (37.9);;
;Others;0 (0.0);0 (0.0);0 (0.0);;
Genetic Analysis;No;55 (21.0);35 (20.0);20 (23.0);0.690;
;Yes;207 (79.0);140 (80.0);67 (77.0);;
Hereditary predisposition;No;159 (77.6);109 (79.0);50 (74.6);0.601;
;Yes;46 (22.4);29 (21.0);17 (25.4);;
Inflammatory BC;No;260 (99.2);173 (98.9);87 (100.0);0.805;
;Yes;2 (0.8);2 (1.1);0 (0.0);;
Clinical Tumor size (mm);;32.0 (20.2);36.8 (21.1);22.2 (13.8);<0.001;
Clinical N stage (TNM);N0;165 (63.2);100 (57.1);65 (75.6);NaN;
;N1;96 (36.8);75 (42.9);21 (24.4);;
;N2;0 (0.0);0 (0.0);0 (0.0);;
;N3;0 (0.0);0 (0.0);0 (0.0);;
SBR grade;Grade I;11 (4.2);8 (4.6);3 (3.4);0.891;
;Grade II;96 (36.8);63 (36.2);33 (37.9);;
;Grade III;154 (59.0);103 (59.2);51 (58.6);;
Histological type;NST;249 (95.0);170 (97.1);79 (90.8);0.060;
;Lobular;6 (2.3);3 (1.7);3 (3.4);;
;Others;7 (2.7);2 (1.1);5 (5.7);;
Neoajuvant chemotherapy;No;118 (45.0);41 (23.4);77 (88.5);<0.001;
;Yes;144 (55.0);134 (76.6);10 (11.5);;
Chemotherapy setting;NAC;144 (55.0);134 (76.6);10 (11.5);NaN;
;Adjuvant;118 (45.0);41 (23.4);77 (88.5);;
;NAC and adjuvant;0 (0.0);0 (0.0);0 (0.0);;
;Chemotherapy without surgery;0 (0.0);0 (0.0);0 (0.0);;
;No;0 (0.0);0 (0.0);0 (0.0);;
Fertility preservation discussion;No;3 (1.1);2 (1.1);1 (1.1);1.000;
;Yes;259 (98.9);173 (98.9);86 (98.9);;
